Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance

被引:27
作者
Clairambault, Jean [1 ]
机构
[1] Hop Paul Brousse, INSERM Rythmes Biol & Canc U776, F-9480 Villejuif, France
[2] INRIA Rocquencourt, F-78153 Le Chesnay, France
关键词
theoretical models; cancer drug toxicity; pharmacokinetics-pharmacodynamics; treatment outcome; Chronotherapy; drug-delivery optimization;
D O I
10.1016/j.addr.2006.08.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To make possible the design of optimal (circadian and other period) time-scheduled regimens for cytotoxic drug delivery by intravenous infusion, a pharmacokinetic-pharmaeodynamic (PK-PD, with circadian periodic drug dynamics) model of chemotherapy on a population of tumor cells and its tolerance by a population of fast renewing healthy cells is presented. The application chosen for identification of the model parameters is the treatment by oxaliplatin of Glasgow osteosarcoma, a murine tumor, and the healthy cell population is the jejunal mucosa, which is the main target of oxaliplatin toxicity in mice. The model shows the advantage of a periodic time-scheduled regimen, compared to the conventional continuous constant infusion of the same daily dose, when the biological time of peak infusion is correctly chosen. Furthermore, it is well adapted to using mathematical optimization methods of drug infusion flow, choosing tumor population minimization as the objective function and healthy tissue preservation as a constraint. Such a constraint is in clinical settings tunable by physicians by taking into account the patient's state of health. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:1054 / 1068
页数:15
相关论文
共 45 条
[1]   Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK-PD model [J].
Barbolosi, D ;
Iliadis, A .
COMPUTERS IN BIOLOGY AND MEDICINE, 2001, 31 (03) :157-172
[2]   Optimisation of time-scheduled regimen for anti-cancer drug infusion [J].
Basdevant, C ;
Clairambault, J ;
Lévi, F .
ESAIM-MATHEMATICAL MODELLING AND NUMERICAL ANALYSIS-MODELISATION MATHEMATIQUE ET ANALYSE NUMERIQUE, 2005, 39 (06) :1069-1086
[3]   Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy [J].
Boldrini, JL ;
Costa, MIS .
IMA JOURNAL OF MATHEMATICS APPLIED IN MEDICINE AND BIOLOGY, 2000, 17 (01) :33-51
[4]  
BOUGHATTAS NA, 1989, CANCER RES, V49, P3362
[5]   COMPARATIVE PHARMACOKINETICS OF OXALIPLATIN (L-OHP) AND CARBOPLATIN (CBDCA) IN MICE WITH REFERENCE TO CIRCADIAN DOSING TIME [J].
BOUGHATTAS, NA ;
HECQUET, B ;
FOURNIER, C ;
BRUGUEROLLE, B ;
TRABELSI, H ;
BOUZOUITA, K ;
OMRANE, B ;
LEVI, F .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1994, 15 (09) :761-773
[6]   A MATHEMATICAL-MODEL FOR CELL-POPULATION KINETICS IN THE INTESTINE [J].
BRITTON, NF ;
WRIGHT, NA ;
MURRAY, JD .
JOURNAL OF THEORETICAL BIOLOGY, 1982, 98 (03) :531-541
[7]   Recognition and processing of cisplatin- and oxaliplatin-DNA adducts [J].
Chaney, SG ;
Campbell, SL ;
Bassett, E ;
Wu, YB .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 53 (01) :3-11
[8]   Circadian rhythm and tumour growth [J].
Clairambault, J ;
Michel, P ;
Perthame, B .
COMPTES RENDUS MATHEMATIQUE, 2006, 342 (01) :17-22
[9]   Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow Osteosarcoma in mice:: a mathematical model. [J].
Clairambault, J ;
Claude, D ;
Filipski, E ;
Granda, T ;
Lévi, F .
PATHOLOGIE BIOLOGIE, 2003, 51 (04) :212-215
[10]  
Edelstein-Keshet L, 1988, MATH MODELS BIOL, p[xvii, 210]